Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Sewkian Rudge has worked on the following 69 EPO patent applications which have been published in the last five years:

EP11755492

COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS

IPC classification:
A61K 31/167, A61K 31/385, A61K 31/395, A61K 31/4045, A61K 31/4152, A61K 31/4965, A61K 31/573, A61K 31/69, A61K 31/706, A61K 38/16, A61K 45/06, A61P 35/00, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11782111

USE OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS

IPC classification:
A61K 31/4439, A61K 31/517, A61K 39/395, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11806079

CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4[2-(PROPANE-2-SULFONYL)-PHENYL]-PYRIMIDINE-2,4-DIAMINE

IPC classification:
A61K 31/506, A61P 35/00, C07D 401/12
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
The patent has been granted
EP12706843

SYNTHESIS OF 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES

IPC classification:
C07D 213/26, C07D 417/04, C07D 417/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12710849

FGFR AND LIGANDS THEREOF AS BIOMARKERS FOR BREAST CANCER IN HR POSITIVE SUBJECTS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12717568

COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR

IPC classification:
A61K 31/436, A61K 31/4439, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12723801

4-AMINO-5-FLUORO-3- [6- (4 -METHYLPIPERAZIN- 1 - YL) - 1H - BENZIMIDAZOL - 2 - YL]- 1H - QUINOLI N-2-ONE FOR USE IN THE TREATMENT OF ADENOID CYSTIC CARCINOMA

IPC classification:
A61K 31/4704, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP12738256

BIOMARKERS FOR HEDGEHOG INHIBITOR THERAPY

IPC classification:
G01N 33/50, G01N 33/574
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12198383

HSP90 inhibitors for therapeutic treatment

IPC classification:
A61K 31/00, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12728285

POLYMORPHS OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-({4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL}-AMIDE

IPC classification:
A61K 31/4439, A61P 35/00, C07D 417/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13155903

Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members

IPC classification:
A61K 31/5377, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12728015

MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-5-(4-METHYL-1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS

IPC classification:
A61K 31/506, A61P 35/00, C07D 401/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12753140

PI3K INHIBITOR FOR USE IN THE TREATMENT OF BONE CANCER OR FOR PREVENTING METASTATIC DISSEMINATION PRIMARY CANCER CELLS INTO THE BONE

IPC classification:
A61K 31/00, A61K 31/506, A61P 35/00, A61P 35/04
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12824789

SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS

IPC classification:
A61K 31/4184, A61K 31/4412, A61K 31/4439, A61K 45/06, A61P 35/00, A61P 43/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12758976

USE OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE IN THE TREATMENT OF CANCER IN MODERATE HEPATIC IMPAIRED PATIENTS

IPC classification:
A61K 31/4709, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12772316

2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

IPC classification:
A61K 31/428, A61K 31/4439, A61K 31/497, A61K 31/506, A61K 35/00, A61K 45/06
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Gill Jennings & Every LLP
Status:
GRANT OF PATENT INTENDED
EP12780391

METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS

IPC classification:
A61K 31/4439, A61K 31/4745, A61K 31/506, A61K 31/5377, A61K 45/06
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14150490

Formulations of quinolinones

IPC classification:
A61K 9/48, A61K 31/496, A61K 47/12, A61K 47/26, A61K 47/32, A61K 47/36, A61P 35/00, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12780497

2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES FOR USE IN TREATING VEGF - DEPENDENT DISEASES

IPC classification:
A61K 31/427, A61K 31/4439, A61P 43/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12795175

METHOD OF TREATING A PROLIFERATIVE DISEASE

IPC classification:
A61K 31/506, A61P 35/00
Applicant:
Novartis AG
Agent:
Zöe Clyde-Watson, D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12798500

IMMEDIATE RELEASE 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-[5-(4-METHYL- 1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE FORMULATION

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/28
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12809882

PHARMACEUTICAL FORMULATIONS

IPC classification:
A61K 9/14, A61K 9/20, A61K 9/48
Applicant:
Array Biopharma, Inc.
Applicant:
Novartis AG
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14165975

Pharmaceutically acceptable salts of quinolinone compounds and their medical use

IPC classification:
A61K 31/4184, A61K 31/4709, A61K 31/496, A61P 35/00, C07D 401/04
Applicant:
Novartis AG
Applicant:
Novartis Vaccines and Diagnostics Inc.
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13703295

COMBINATION OF A RTK INHIBITOR WITH AN ANTI - ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/138, A61K 31/4535, A61K 31/4709, A61K 31/496, A61K 31/5377, A61K 31/56, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13717371

COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA

IPC classification:
A61K 31/427, A61K 31/4439, A61K 31/497, A61K 31/506, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP13715169

PHARMACEUTICAL DIAGNOSTIC

IPC classification:
A61K 31/4439, A61P 35/00, C12N 15/11, C12Q 1/68, G11B 20/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13717779

TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES

IPC classification:
A61K 9/00, A61K 31/4155, A61K 45/06, A61P 17/00, A61P 17/06
Applicant:
Novartis AG
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP11770611

PHARMACEUTICAL COMBINATIONS

IPC classification:
A61K 31/4188, A61K 31/4745, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13729120

DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR

IPC classification:
A61K 31/5377
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13729566

COMBINATION OF A 17 -ALPHA -HYDROXYLASE (C17, 20 - LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE

IPC classification:
A61K 31/00, A61K 31/4745, A61K 31/496, A61K 31/506, A61K 31/58, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13734068

COMBINATION OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND AN INHIBITOR OF THE IL-8/CXCR INTERACTION

IPC classification:
A61K 31/145, A61K 31/4188, A61K 39/00, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Applicant:
Friedrich Miescher Institute For Biomedical Research
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13745540

PHARMACEUTICAL COMBINATIONS OF A CDK4/6 INHIBITOR AND A B-RAF INHIBITOR

IPC classification:
A61K 31/4184, A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13748243

PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR

IPC classification:
A61K 31/4439, A61K 31/506, A61K 31/517, A61P 35/00
Applicant:
Novartis AG
Agent:
D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13751058

COMBINATION OF PI3K INHIBITOR AND C-MET INHIBITOR

IPC classification:
A61K 31/427, A61K 31/4745, A61K 31/5377, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13835019

METHOD OF ADJUVANT CANCER TREATMENT

IPC classification:
A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13770771

PHARMACEUTICAL COMBINATION COMPRISING A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR AND AN AROMATASE INHIBITOR

IPC classification:
A61K 31/4184, A61K 31/4196, A61K 31/4439, A61K 31/445, A61K 31/566, A61K 31/5685, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13779841

IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE

IPC classification:
C07D 239/28, C07D 239/42, C07D 401/04, C07D 401/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
PATENT GRANTED
EP13798786

COMBINATION THERAPY

IPC classification:
A61K 31/506, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Gill Jennings & Every LLP
Status:
EXAMINATION REQUESTED
EP11784238

COMBINATION

IPC classification:
A61K 31/4155, A61K 31/517, G01N 33/574
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
PATENT GRANTED
EP12733916

COMBINATION

IPC classification:
A01N 43/56, A61K 31/4155, A61K 31/69, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11787314

COMBINATION

IPC classification:
A61K 31/16, A61K 31/40, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11820572

PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Applicant:
GlaxoSmithKline LLC
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15171908

PROCESS FOR PURIFYING STAUROSPORINE

IPC classification:
C07D 498/22
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14710642

ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG

IPC classification:
A61K 9/10, A61K 31/00, A61K 47/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14711613

FORMULATIONS OF ORGANIC COMPOUNDS

IPC classification:
A61K 9/16, A61K 9/20, A61K 31/5377, A61K 35/00, A61K 47/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
PATENT GRANTED
EP14731782

COMBINATION OF A PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN THE TREATMENT OR PREVENTION OF A CANCER OF THE HEAD AND NECK

IPC classification:
A61K 31/337, A61K 31/506, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14730595

COMBINATIONS OF AN ANTI-PD-L1 ANTIBODY AND A MEK INHIBITOR AND/OR A BRAF INHIBITOR

IPC classification:
A61K 9/20, A61K 31/506, A61K 31/519, A61K 39/395, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15190917

TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES

IPC classification:
A61K 38/13, A61P 1/16, A61P 31/14, A61P 31/20
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14759280

PHARMACEUTICAL COMBINATIONS

IPC classification:
A61K 31/444, A61K 31/4745, A61K 31/506, A61K 45/06
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP15184282

PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB

IPC classification:
A61K 9/16, A61K 31/506, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14752432

PIM KINASE INHIBITOR COMBINATIONS

IPC classification:
A61K 31/4439, A61K 31/444, A61K 31/519, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11710200

PREPARATION OF HYDRATED POLYMORPHS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALT

IPC classification:
C07D 401/04
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11714304

COMBINATION OF ORGANIC COMPOUNDS

IPC classification:
A61K 31/00, A61K 31/436, A61K 31/496, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP16151719

CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR

IPC classification:
A61K 31/535, A61P 35/00, C07D 401/04
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14790344

ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/4155, A61K 31/4166, A61K 31/58, A61K 45/06, A61P 35/00, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14790343

COMBINATION

IPC classification:
A61K 31/4155, A61K 31/4375, A61K 31/58, A61K 45/06, A61P 35/00, A61P 35/04, A61P 43/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11713996

PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING

IPC classification:
A61K 31/00, A61K 31/404, A61K 31/407, A61K 31/436, A61K 31/499, A61K 31/517, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11851046

Combination therapy comprising Gemcitabine for the treatment of pancreatic cancer

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/48, A61K 31/519, A61K 31/7068, A61P 35/00
Applicant:
Novartis AG
Agent:
Michael Antony Reed, GlaxoSmithKline
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
PATENT GRANTED
EP13154400

Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members

IPC classification:
A61K 31/5377, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14812658

DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR

IPC classification:
A61K 31/4439, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14819083

COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/506, A61K 31/519, A61K 39/395, A61P 35/00, A61P 35/02, A61P 35/04
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15701257

PHARMACEUTICAL COMBINATIONS

IPC classification:
A61K 31/138, A61K 31/4439, A61K 31/4535, A61K 31/5377, A61K 38/09, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16159264

BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS

IPC classification:
A01N 43/42, A61K 31/427, C07D 413/04, C07D 413/14, C07D 417/04, C07D 417/14
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
Request for examination was made
EP15704384

PHARMACEUTICAL COMBINATIONS COMPRISING A PI3K INHIBITOR FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/436, A61K 31/4439, A61K 31/5685, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15708605

COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR

IPC classification:
A61K 31/4155, A61K 31/519, A61K 45/06, A61P 35/00, A61P 35/02
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15744704

SOLID PHARMACEUTICAL COMPOSITION COMPRISING PI3K-INHIBITOR

IPC classification:
A61K 9/14, A61K 9/20, A61K 9/48, A61K 31/5377
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis AG
Status:
EXAMINATION REQUESTED
EP15788239

COMBINATION THERAPIES OF EGFR INHIBITORS

IPC classification:
A61K 31/506, A61K 31/55, A61K 39/00, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis AG
Status:
Request for examination was made
EP15781518

USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

IPC classification:
A61K 31/4353, A61K 31/437, A61K 31/4375, A61K 31/501, A61K 31/506, A61K 31/5377, A61K 31/5383, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis AG
Status:
Request for examination was made
EP15778761

PHARMACEUTICAL COMPOSITIONS COMPRISING ALPELISIB

IPC classification:
A61K 9/20, A61K 31/00, A61P 35/00
Applicant:
Novartis AG
Agent:
Sewkian Rudge, Novartis AG
Status:
Request for examination was made

Please Sign in to use this feature